Literature DB >> 20186146

Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.

Ryutaro Yamanaka1, Fumio Otsuka, Kazufumi Nakamura, Misuzu Yamashita, Hiroyuki Otani, Masaya Takeda, Yoshinori Matsumoto, Kengo F Kusano, Hiroshi Ito, Hirofumi Makino.   

Abstract

Recent genetic studies have uncovered a link between familial and idiopathic pulmonary arterial hypertension (PAH) and germline mutations in the bone morphogenetic protein type-II receptor (BMPRII). The pathology of PAH is characterized by remodeling of the pulmonary arteries due to pulmonary artery smooth muscle cell (PASMC) hyperproliferation. Although increased endothelial injury and impaired suppression of PASMC proliferation are both critical for the cellular pathogenesis of PAH, a detailed molecular mechanism underlying PAH has yet to be elucidated. In the present study, we investigated the roles of the BMP system and other vasoactive factors associated with PAH (including endothelin (ET), angiotensin II (Ang II) and aldosterone) in the mitotic actions of PASMCs isolated from idiopathic and secondary PAH lungs. ET1 and aldosterone stimulated PASMC proliferation of idiopathic PAH more effectively than secondary PAH, whereas Ang II and ET3 failed to activate mitosis in either of the PASMC cell type. The effects of ET1 and aldosterone were blocked by bosentan, an ET type-A/B receptor (ETA/BR) antagonist, and eplerenone, a selective mineralocorticoid receptor (MR) blocker, respectively. Among the BMP ligands examined, BMP-2 and BMP-7, but not BMP-4 or BMP-6, significantly increased cell mitosis in both PASMC cell types. Notably, ET1- and aldosterone-induced mitosis and mitogen-activated protein kinase phosphorylation were significantly increased in the presence of BMP-2 and BMP-7 in PASMCs isolated from idiopathic PAH, although additive effects were not observed in PASMCs isolated from secondary PAH. Inhibition of extracellular signal-regulated kinase 1 (ERK1)/ERK2 signaling suppressed basal-, ET1- and aldosterone-induced PASMC mitosis more potently than that of stress-activated protein kinase/c-Jun NH2-terminal kinase inhibition. Given the fact that BMP-2 and BMP-7 upregulated ETA/BR and MR expression and that BMP-2 decreased 11betaHSD2 (11beta-hydroxysteroid dehydrogenase type 2) levels in PASMCs isolated from idiopathic PAH, BMPR-Smad signaling may have a key role in amplifying the ETA/BR and/or MR-ERK signaling in PASMCs of the PAH lung. Collectively, the functional link between BMP and ET and/or the MR system may be involved in the progress of PASMC mitosis, ultimately leading to the development of clinical PAH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186146     DOI: 10.1038/hr.2010.16

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  12 in total

1.  Pulmonary hypertension: have we learned enough yet?

Authors:  Davide Cattano; Marie Francoise Doursout
Journal:  Intern Emerg Med       Date:  2012-08-18       Impact factor: 3.397

Review 2.  Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

3.  Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells.

Authors:  Michael E Yeager; Dmitry D Belchenko; Cecilia M Nguyen; Kelley L Colvin; D Dunbar Ivy; K R Stenmark
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01       Impact factor: 6.914

4.  Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension.

Authors:  Paolo Calabrò; Giuseppe Limongelli; Valeria Maddaloni; Carmine Dario Vizza; Michele D'Alto; Raffaella D'Alessandro; Roberto Poscia; Paola Argiento; Brunella Ziello; Roberto Badagliacca; Emanuele Romeo; Giuseppe Pacileo; Maria Giovanna Russo; Francesco Fedele; Raffaele Calabrò
Journal:  Intern Emerg Med       Date:  2011-07-20       Impact factor: 3.397

5.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Rod R Warburton; Nicholas S Hill; Barry L Fanburg; Iris Z Jaffe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

6.  Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis.

Authors:  Bradley A Maron; William M Oldham; Stephen Y Chan; Sara O Vargas; Elena Arons; Ying-Yi Zhang; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2014-04-28       Impact factor: 29.690

7.  Endothelin but Not Angiotensin II May Mediate Hypertension-Induced Coronary Vascular Calcification in Chronic Kidney Disease.

Authors:  Simon W Rabkin
Journal:  Int J Nephrol       Date:  2011-05-31

8.  Commentary: Bone morphogenetic protein's contribution to pulmonary artery hypertension: Should this raise concern for patients undergoing spinal fusions with bone morphogenetic protein?

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2014-12-30

9.  Multi-omics analysis reveals regulators of the response to PDGF-BB treatment in pulmonary artery smooth muscle cells.

Authors:  Jidong Chen; Xiaolei Cui; Zhengjiang Qian; Yanjiao Li; Kang Kang; Junle Qu; Li Li; Deming Gou
Journal:  BMC Genomics       Date:  2016-10-06       Impact factor: 3.969

10.  Adrenomedullin and adrenotensin regulate collagen synthesis and proliferation in pulmonary arterial smooth muscle cells.

Authors:  W Li; Q Y Kong; C F Zhao; F Zhao; F H Li; W Xia; R Wang; Y M Hu; M Hua
Journal:  Braz J Med Biol Res       Date:  2013-12-10       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.